-
Sep 30, 2024 | 02605-8/abstract?rss=yes&sz=64)
europeanurology.com | Roger Li |Joshua A. Linscott |James Catto |Joshua J. Meeks |Siamak Daneshmand |Bishoy M Faltas | +4 more
Property Value Status Version Ad File Disable Ads Flag Environment Moat Init Moat Ready Contextual Ready Contextual URL Contextual Initial Segments Contextual Used Segments AdUnit SubAdUnit Custom Targeting Ad Events Invalid Ad Sizes aDepartment of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USAbDepartment of Immunology, H.
-
Sep 4, 2024 | 
urotoday.com | Roger Li
Read the Full Video TranscriptAshish Kamat: Hello, everybody, and welcome to UroToday's Bladder Cancer Center of Excellence. I'm Ashish Kamat, and I'm joined today by Professor Roger Li, who has been on this platform many times, spending a lot of time sharing his insights into novel therapies and trials.
-
Sep 4, 2024 | 
urotoday.com | Roger Li
Read the Full Video TranscriptAshish Kamat: Hello, everybody, and welcome to UroToday's Bladder Cancer Center of Excellence. I'm Ashish Kamat, and I'm joined today by Professor Roger Li, who has been on this platform many times, spending a lot of time sharing his insights into novel therapies and trials.
-
Aug 30, 2024 | 
onclive.com | Roger Li
CommentaryVideoAugust 30, 2024Roger Li, MD, discusses safety data from the final analysis of the CORE-001 trial in BCG-unresponsive non–muscle-invasive bladder cancer.
-
Aug 29, 2024 | 
onclive.com | Roger Li
CommentaryVideoAugust 29, 2024Fact checked by:Roger Li, MD, discusses the final analysis of the CORE-001 trial of cretostimogene grenadenorepvec plus pembrolizumab in BCG-unresponsive NMIBC with CIS.
-
Aug 22, 2024 | 
onclive.com | Roger Li
CommentaryVideoAugust 22, 2024Roger Li, MD, discusses the implications of a post hoc analysis of the KEYNOTE-057 trial in BCG-unresponsive, high-risk non–muscle-invasive bladder cancer.
-
Aug 13, 2024 | 
onclive.com | Roger Li
CommentaryVideoAugust 13, 2024Roger Li, MD, details a post hoc analysis of patients with BCG-unresponsive non–muscle-invasive bladder cancer who did not respond to pembrolizumab.
-
Jul 24, 2024 | 
digitalcommons.library.tmc.edu | Andrea Necchi |Philippe E. Spiess |Roger Li |Petros Grivas
IMPORTANCE: Tumor mutational burden (TMB) is a putative biomarker of efficacy for immune checkpoint inhibitor (ICI) therapies of solid tumors, but not specifically for penile squamous cell carcinoma (PSCC). OBJECTIVE: To characterize biomarker features and ICI therapy outcomes associated with high TMB in PSCC in the routine clinical practice setting.
-
Jul 23, 2024 | 
onclive.com | Roger Li
Roger Li, MD, genitourinary oncologist, Moffitt Cancer Center, discusses persisting unmet needs and potential avenues of research for patients with high-risk, muscle-invasive bladder cancer (MIBC). Li begins by explaining that patients with Bacillus Calmette–Guérin (BCG)–unresponsive, high-risk, non–muscle-invasive bladder cancer (NMIBC) have historically been a difficult population to treat.
-
Jul 2, 2024 | 
nature.com | Roger Li |Joshua J. Meeks |Ashish M. Kamat
Correction to: Nature Medicine https://doi.org/10.1038/s41591-024-03025-3, published online 6 June 2024In the version of the article initially published, in the key to Fig. 2b, the red diamond representing “Recurrence/NR” has been corrected to a green diamond to match the graph. This correction has been made to the HTML and PDF versions of the article. About this articleLi, R., Shah, P.H., Stewart, T.F. et al.
